Bortezomib in relapsed or refractory myeloma patients

被引：0
|
作者：
Leonetti Crescenzi, S. [1 ]
Piccioni, A. L. [1 ]
Bagnato, A. [1 ]
机构：
[1] Osped Sandro Pertini, UOC Ematol, ASL Roma B, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [11] Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [12] Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma
    Zangari, Maurizio
    Guerrero, Jose
    Cavallo, Federica
    Prasad, H. Keshava
    Esseltine, Dixie
    Fink, Louis
    HAEMATOLOGICA, 2008, 93 (06) : 953 - 954
  • [13] Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher A.
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    BLOOD, 2016, 128 (22)
  • [14] PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
    Richardson, Paul G.
    Schlossman, Robert L.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Gasparetto, Cristina
    Mukhopadhyay, Sutapa
    Ondovik, Michael S.
    Khan, Mahmudul
    Paley, Carole S.
    Lonial, Sagar
    BLOOD, 2013, 122 (14) : 2331 - 2337
  • [15] Response to Bortezomib in relapsed/refractory multiple myeloma serie
    Rubio-Martinez, A.
    Recasens, V.
    Montanes, M. A.
    Mayayo, P.
    Delgado, P.
    Garcia-Zueco, J. C.
    Rubio-Felix, D.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 165 - 166
  • [16] Safety and Efficacy of Bortezomib in Refractory/Relapsed Multiple Myeloma
    Lalagianni, C. E.
    Neokleous, N.
    Vadikoliou, C.
    Papalexandri, A.
    Apostolou, C.
    Saloum, R.
    Anagnostopoulos, A.
    Fassas, A.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S26 - S26
  • [17] The challenge of relapsed/refractory myeloma: An emerging role of bortezomib
    Vyasal, Bhargav
    Maseeh, Arun
    CLINICAL CANCER INVESTIGATION JOURNAL, 2012, 1 (04): : 190 - 195
  • [18] Carfilozomib versus bortezomib for relapsed or refractory myeloma Reply
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Palumbo, Antonio
    Chng, Wee-Joo
    Feng, Shibao
    LANCET ONCOLOGY, 2016, 17 (04): : E126 - E126
  • [19] A phase 2 study of bortezomib in relapsed, refractory myeloma
    Richardson, PG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, SV
    Srkalovic, G
    Alsina, M
    Alexanian, R
    Siegel, D
    Orlowski, RZ
    Kuter, D
    Limentani, SA
    Lee, S
    Hideshima, T
    Esseltine, DL
    Kauffman, M
    Adams, J
    Schenkein, DP
    Anderson, KC
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26): : 2609 - 2617
  • [20] Response to bortezomib in relapsed/refractory multiple myeloma cohort
    Rubio-Martinez, A.
    Recasens, V.
    Montanes, M. A.
    Mayayo, P.
    Delgado, P.
    Garcia-Zueco, J. C.
    Rubio-Felix, D.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 472 - 472
12345